Table 2. Progression free survival (univariate and multivariate analysis).
| Characteristics | Univariate | Multivariate |
|---|---|---|
| Sex | P=0.3 (0.4–1.3) | P=0.6 (0.5–2.4) |
| Male | ||
| Female | ||
| Age ≥75 | P=0.5 (0.3–1.6) | P=0.4 (0.6–3.3) |
| Yes | ||
| No | ||
| TPS score | P=0.06 (0.08–0.65) | P=0.06 (0.2–1.0) |
| 0% | ||
| <1% | ||
| 1–49% | ||
| ≥50% | ||
| Immunotherapy | P=0.5 (0.4–1.6) | P=0.8 (0.4–2.4) |
| Pembrolizumab | ||
| Atezolizumab | ||
| Ipilimumab | ||
| Ipilimumab/nivolumab | ||
| Line of therapy | P=0.006 (0.2–0.5) | P=0.005 (0.7–0.9) |
| ICI + denosumab duration | P=0.006 (0.2–0.7) | P=0.0002 (0.1–0.4) |
| <3 months | ||
| >3 months | ||
| Radiation therapy | P=0.2 (0.4–1.2) | P=0.7 (0.5–2.0) |
| Yes | ||
| No | ||
| Skeletal metastases | P=0.1 (0.8–2.5) | P=0.7 (0.4–2.7) |
| <3 | ||
| >3 | ||
| Brain metastases | P=0.3 (0.7–2.2) | P=0.3 (0.6–3.24) |
| Yes | ||
| No | ||
| Number of metastatic sites | P=0.05 (0.9–2.9) | P=0.03 (1.1–10.1) |
| 1–3 sites | ||
| >3 sites | ||
| LDH | P=0.5 (0.6–2.4) | P=0.3 (0.2–1.5) |
| >220 IU | ||
| <220 IU | ||
TPS, tumor proportion score; ICI, immune checkpoint inhibitors; LDH, lactate dehydrogenase.